RecruitingNCT06791941

Study of the Contribution of Mutant p53/YAP Proteins to Therapy Resistance in Recurrent Head and Neck Cancer

Sponsor

Regina Elena Cancer Institute

Enrollment

18 participants

Start Date

Mar 7, 2024

Study Type

OBSERVATIONAL

Conditions

Head and Neck Tumors

Summary

Multicenter, non-interventional, retrospective/prospective study of a biological nature, on patients affected by head and neck tumors, for which the collection and use of tissue samples is planned for the study of the mutational profile, the transcriptional profile and the proteomic profile.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study investigates why some head and neck cancers stop responding to treatment. Researchers are looking at two proteins — mutant p53 and YAP — that may help cancer cells survive despite therapy. Tumor samples from patients are analyzed to understand these resistance patterns. **You may be eligible if...** - You are over 18 and have been diagnosed with squamous cell cancer of the mouth, throat, or voice box - You are scheduled for surgery to remove the tumor and have not had prior cancer treatment - Your tumor tissue can be provided for analysis - At least one year of follow-up data is available (for the retrospective portion) **You may NOT be eligible if...** - Your cancer has already spread to distant parts of the body - You have had head and neck cancer before - You are currently being treated for another cancer Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALCulture of organoids

Culture of organoids prepared from both the primary tumor and the respective relapse, using the material from the prospective part of the study, the response to treatment will be carried out by macroscopic analysis, evaluating the size and number of organoids before and after treatment,

Locations(1)

IRCCS National Cancer institute

Roma, Rome, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06791941

Related Trials

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

NCT064798111 location

Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors

NCT075524671 location

Multiparametric Imaging-based Intraoperative Navigation for Guidance of Surgical Resection and Postoperative Radiotherapy in Patients With Head-and-neck Tumors

NCT056714581 location

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

NCT057583891 location

Correlation and Predictive Research of Metal Elements in Radiation-Induced Oral Mucositis

NCT069685201 location